Vaxcyte
PCVX
295 hedge funds and large institutions have $6.81B invested in Vaxcyte in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 95 increasing their positions, 106 reducing their positions, and 45 closing their positions.
86% more funds holding in top 10
Funds holding in top 10: 7 → 13 (+6)
36% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 45
34% more capital invested
Capital invested by funds: $5.09B → $6.81B (+$1.72B)
3.91% more ownership
Funds ownership: 108.82% → 112.72% (+3.9%)
4% more funds holding
Funds holding: 285 → 295 (+10)
10% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 106
41% less call options, than puts
Call options by funds: $6.32M | Put options by funds: $10.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$133M |
| 2 |
CP
Caligan Partners
New York
|
+$76.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$62.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$56.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$55.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$42M |
| 3 |
D.E. Shaw & Co
New York
|
-$29.5M |
| 4 |
Comerica Bank
Dallas,
Texas
|
-$29.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$23.9M |
PCVX Hedge Fund Activity: Q4 2025 in Review
295 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2025, worth a combined $6.81B — up 34% from $5.09B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new PCVX positions and 45 closed out — a net gain of 16 holders — while 95 added to existing stakes and 106 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $133M. The largest seller was RA Capital Management, cutting an estimated $55.5M.
- 295 institutional investors held Vaxcyte (PCVX) as of Q4 2025, up from 285 in Q3 2025.
- Funds reported $6.81B of Vaxcyte stock for Q4 2025, up 34% quarter-over-quarter.
- 61 funds opened new Vaxcyte positions in Q4 2025 and 45 closed out, a net change of +16 holders.
- The largest Vaxcyte buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $133M added.
- The largest Vaxcyte seller in Q4 2025 was RA Capital Management, an estimated $55.5M sold.
Based on aggregated 13F filings for Q4 2025.